WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences
WIRB-Copernicus Group announced that it has acquired Alliance Biosciences.
WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services for clinical research, announced that it has acquired Alliance Biosciences. Alliance Biosciences was the leading biosafety and biosecurity consulting firm in the United States and will join WCG’s biosafety division – WCG Biosafety™ – to manage the entire continuum of biosafety oversight, helping to ensure that research involving potentially hazardous agents and vectors complies with the appropriate safety and regulatory requirements from laboratory design and drug discovery through clinical testing and therapeutic application. WCG Biosafety manages more than 200 Institutional Biosafety Committees (IBCs) and has evaluated more than 140 gene transfer clinical and recombinant DNA pre-clinical research protocols to date.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
HHS Cancels Moderna Grant for Late-Stage Development of mRNA Vaccine Candidate
June 4th 2025Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s award for almost $600 million to accelerate vaccine development will be terminated.
